Page 67 - Read Online

Wang et al. Genotoxic NF-kB activation in cancer

Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart Song JS, Fisher DE. Chromatin structure analyses identify miRNA
CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill promoters. Genes Dev 2008;22:3172-83.
DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts 155. Kato M, Paranjape T, Muller RU, Nallur S, Gillespie E, Keane K,
TM, Lander ES, Polyak K, Hahn WC. Integrative genomic approaches Esquela-Kerscher A, Weidhaas JB, Slack FJ. The mir-34 microRNA
identify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-79. is required for the DNA damage response in vivo in C. elegans and in
137. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. vitro in human breast cancer cells. Oncogene 2009;28:2419-24.
Cell 2011;144:646-74. 156. Chaudhry MA, Sachdeva H, Omaruddin RA. Radiation-induced
138. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell micro-RNA modulation in glioblastoma cells differing in DNA-repair
2004;6:203-8. pathways. DNA Cell Biol 2010;29:553-61.
139. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic 157. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender
targets in cancer. Cell Death Differ 2006;13:738-47. L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW,
140. Melisi D, Chiao PJ. NF-kappa B as a target for cancer therapy. Expert Cleary MA, Hannon GJ. A microRNA component of the p53 tumour
Opin Ther Targets 2007;11:133-44. suppressor network. Nature 2007;447:1130-4.
141. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. Alkylating 158. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-
agents induce activation of NFkappaB in multiple myeloma cells. dependent induction of microRNA miR-146, an inhibitor targeted to
Leuk Res 2008;32:1144-7. signaling proteins of innate immune responses. Proc Natl Acad Sci U
142. Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ. Active S A 2006;103:12481-6.
roles for inhibitory kappaB kinases alpha and beta in nuclear factor- 159. Zhou R, Hu G, Liu J, Gong AY, Drescher KM, Chen XM. NF-
kappaB-mediated chemoresistance to doxorubicin. Mol Cancer Ther kappaB p65-dependent transactivation of miRNA genes following
2008;7:1827-35. Cryptosporidium parvum infection stimulates epithelial cell immune
143. Baldwin AS. Control of oncogenesis and cancer therapy resistance by responses. PLoS Pathog 2009;5:e1000681.
the transcription factor NF-kappaB. J Clin Invest 2001;107:241-6. 160. Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F,
144. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Maroulakou I, Struhl K, Tsichlis PN. Akt2 regulates all Akt isoforms
Mizuno T, Tohyama M. Tumor necrosis factor induces Bcl-2 and Bcl-x and promotes resistance to hypoxia through induction of miR-21 upon
expression through NFkappaB activation in primary hippocampal oxygen deprivation. Cancer Res 2011;71:4720-31.
neurons. J Biol Chem 1999;274:8531-8. 161. Ruan Q, Wang T, Kameswaran V, Wei Q, Johnson DS, Matschinsky
145. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF- F, Shi W, Chen YH. The microRNA-21-PDCD4 axis prevents type 1
kappaB controls cell growth and differentiation through transcriptional diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci U
regulation of cyclin D1. Mol Cell Biol 1999;19:5785-99. S A 2011;108:12030-5.
146. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp 162. Niu J, Shi Y, Tan G, Yang CH, Fan M, Pfeffer LM, Wu ZH. DNA damage
J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap induces NF-κB-dependent microRNA-21 up-regulation and promotes
gene expression protects endothelial cells from tumor necrosis factor breast cancer cell invasion. J Biol Chem 2012;287:21783-95.
alpha-induced apoptosis. J Exp Med 1998;188:211-6. 163. Niu J, Xue A, Chi Y, Xue J, Wang W, Zhao Z, Fan M, Yang CH,
147. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Shao ZM, Pfeffer LM, Wu J, Wu ZH. Induction of miRNA-181a
Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo by genotoxic treatments promotes chemotherapeutic resistance and
HS, Hwang ES, Jirström K, West BL, Coussens LM. Leukocyte metastasis in breast cancer. Oncogene 2016;35:1302-13.
complexity predicts breast cancer survival and functionally regulates 164. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB,
response to chemotherapy. Cancer Discov 2011;1:54-67. Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NMB, Jackson
148. Naugler WE, Karin M. The wolf in sheep’s clothing: the role of SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA
interleukin-6 in immunity, inflammation and cancer. Trends Mol Med mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
2008;14:109-19. 165. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E,
149. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-
cancer. Cell 2010;140:883-99. deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
150. White NMA, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Nature 2005;434:913-7.
Metastamirs: a stepping stone towards improved cancer management. 166. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey
Nat Rev Clin Oncol 2011;8:75-84. LA. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for
151. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, triple-negative breast cancer. Clin Cancer Res 2010;16:4702-10.
Croce CM. Breast cancer signatures for invasiveness and prognosis 167. Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer.
defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A Curr Opin Pharmacol 2006;6:364-8.
2012;109:3024-9. 168. Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit
152. Lujambio A, Lowe SW. The microcosmos of cancer. Nature C. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA
2012;482:347-55. damage-induced IkappaB kinase activation. Mol Cell 2009;36:365-78.
153. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and 169. Hunter JE, Willmore E, Irving JA, Hostomsky Z, Veuger SJ, Durkacz
function. Cell 2004;116:281-97. BW. NF-κB mediates radio-sensitization by the PARP-1 inhibitor,
154. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, Zhang X, AG-014699. Oncogene 2012;31:251-64.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ March 27, 2017 59